BCHC submits comments to CDC on DoxyPEP guidelines
BCHC issued comments to CDC’s Division of STD Prevention on the proposed guidelines for the use of Doxycycline Post-Exposure Prophylaxis for bacterial sexually transmitted infection (STI) prevention.
We strongly support these guidelines to offer doxycycline as sexually transmitted infection post-exposure prophylaxis (DoxyPEP), which will establish a public health intervention that will bring the nation’s STI rates down and empower individuals to take charge of their health in a new and meaningful way.
We are particularly supportive of the following:
- The strength of recommendation and quality of evidence designation.
- The three criteria for the intervention: (1) taken within 72 hours of oral, vaginal, or anal sex; (2) for gay, bisexual, and other men who have sex with men, and for transgender women; (3) who have a history of at least one bacterial STI in the last 12 months.
- The specification of STI screening at anatomic sites of exposure.
- STI screening every 3-6 months (with clarifications requested below).
- Routine counseling on HIV preexposure prophylaxis (PrEP) for individuals not living with HIV who are not receiving HIV PrEP (with strengthened language requested below).
- The inclusion of transgender women in the recommendation.
- The inclusion of language instructing providers to “provide enough doses of doxy until next follow-up visit, based on individual assessment through shared decision making”.
Specific recommendations include: